Funding source: EU Regional Funds
Funding Institution: Agency for Science, Innovation and Technology of Lithuania
Grant Agreement No. 01.2.1-MITA-T-852-01-0106
Acute respiratory syndrome is the most common COVID-19 infection complication that might lead to death. One of the major causes of respiratory failure induced by the SARS-CoV-2 virus is extensive inflammatory response that damages cells of the respiratory system and impairs their function. To date, no effective therapeutic strategies have been developed to prevent COVID-19-induced acute respiratory distress, and the development of such strategies is of paramount importance. The project seeks to respond to this global need by developing a new cellular exosome biotechnology preparation for the prevention and treatment of acute respiratory failure caused by COVID-19 infection.
